Found 6 clinical trials
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Historically, medulloblastoma treatment has been determined by the amount of leftover disease present after surgery, also known as clinical risk (standard vs. high risk). Recent studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment. This suggests that clinical risk alone is not …
- 144 views
- 25 May, 2022
- 1 location
Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation
This research study is studying proton radiation as a possible treatment for brain tumor that requires radiation. The radiation involved in this study is: -Proton Radiation
- 3 views
- 27 Jan, 2021
- 2 locations
Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.
the dose to the craniospinal axis and keeping the total tumor bed dose the same in this study the investigators are expecting to reduce some of the late side effects of craniospinal irradiation
- 0 views
- 13 Oct, 2021
- 1 location
Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor
The purpose of this study is to evaluate the outcome of intracranial non-germinomatous germ cell tumor (NGGCT) treated with reduced radiotherapy following high dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT).
- 1 views
- 25 Jan, 2021
- 1 location
The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors
Primary endpoint three-year disease-free survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation Health-related quality of life measured by PedsQL 4.0 and SF-36 Second endpoint three-year overall survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation Adverse effects of chemoradiotherapy measured by …
- 0 views
- 25 Nov, 2021
- 1 location
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT)
This study incorporates alisertib, the small-molecule inhibitor of Aurora A activity, in the treatment of patients younger than 22 years of age. Patients with recurrent or refractory AT/RT or MRT will receive alisertib as a single agent. Patients with newly diagnosed AT/RT will receive alisertib as part of age- and …
- 78 views
- 09 Apr, 2022
- 9 locations